Session Description:

Join us for a virtual symposium Amyloid-β Pathway: Evolving Scientific Knowledge and Clinical Implications for Alzheimer’s Disease. In the past 30 years leading up to and since the proposal of the Amyloid Cascade Hypothesis, our understanding of the amyloid pathway in Alzheimer’s disease (AD) has evolved and refined, culminating in therapeutic development based on amyloid-β (Aβ) as a target. Focusing on the dynamic nature of the Aβ pathway across time and space, this symposium will review the clinical evidence and biological rationale of what, when, and where amyloid species may be clinically meaningful and their relevance to AD etiology, diagnosis, and treatment development. The esteemed faculty will discuss the current understanding of Aβ in AD, provide their perspectives on the latest advances, and lay out the foundational concepts linking non-clinical research to disease relevance. They will discuss how Aβ is not a singular entity but exists in various forms and cellular compartments, and how these components may have implications in disease characterization and therapeutic implications. The speakers will also review clinical and nonclinical studies that can explain Aβ related functional changes in the brain in health and AD, and biological underpinnings of Aβ biomarkers that may help track disease progression and guide treatment decision-making.